Premium Information is available for this item - Upgrade for $1 a day

6505-01-091-7535

Usp Aspirin And Codeine Phosphate Tablets

6505010917535 010917535 NDC00081-0225-25 0081-0225-25 374 EMPIRIN W/ CODEINE

6505-01-091-7535 ASPIRIN AND CODEINE PHOSPHATE TABLETS,USP 6505010917535 010917535

Managed by United States
NSN Created on 12 Mar 1980
Data Last Changed
November 2023
NATO Update Count
9
NATO Data Quality
6505-01-091-7535 ASPIRIN AND CODEINE PHOSPHATE TABLETS,USP 6505010917535 010917535 1/1
NSN 6505-01-091-7535 (Generic Image) 1/1

6505-01-091-7535 Stock and Availability Marketplace 6505-01-091-7535

6505-01-091-7535 Related Documents Related Documents 6505-01-091-7535 5+ Documents (More...)

Active) Canceled/Obsolete RNCC 5 RNVC 9 DAC 3 09979 https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-091-7535
Codeine Phosphate Tablets Phosphate Tablets6505001182347 001182347 NDC00081-0220-25 ASCODEEN EMPIRIN W/CODEINE
DAC 4 ASCODEEN 09979 AMC 0 AMSC 0 AAC L Approved Sources 6505-01-091-7535 Part NumberManufacturerStatusNDC00081
Aspirin And Codeine Phosphate Tablets6505010861992 010861992 0081-0220-75 NDC00081-0220-75 361 EMPIRIN W/ CODEINE
Usp Aspirin And Codeine Phosphate Tablets 6505-01-091-7535 https//www.nsnlookup.com /fsg-65/fsc
65/fsc-6505/us 6505-00-118-2347 Usp Aspirin And Codeine Phosphate Tablets fsg-65/fsc-6505/us 6505-01-091-7535
And Codeine Phosphate Tablets Aspirin And Codeine Phosphate Tablets 149-0116 6505-01-086-1992 6505-01-091-7535
33-189-8666 6505-33-000-4040 Aspirin And Codeine Phosphate Tablets 149-0116 6505-01-086-1992 6505-01-091-7535
33-189-8666 6505-33-000-4040 Aspirin And Codeine Phosphate Tablets 149-0116 6505-01-086-1992 6505-01-091-7535
Usp Aspirin And Codeine Phosphate Tablets 6505-01-086-1992 6505-01-091-7535 Stock Numbers Related
to 6505-00-959-4331 6505-00-118-2347 6505-00-149-0116 5 RNVC 9 DAC 4 EMPIRIN W/CODEINE Stock Numbers
Related to 6505-00-118-2347 6505-00-118-2347 6505-00-149-0116 6505-01-086-1992 6505-01-091-7535 https
2347Usp Aspirin And Codeine Phosphate Tablets6505001182347 001182347 NDC00081-0220-25 ASCODEEN EMPIRIN W/CODEINE
Usp Aspirin And Codeine Phosphate Tablets 6505-00-149-0116 6505-01-086-1992 6505-01-091-7535 Stock
/es 6505-33-000-4040 Aspirin And Codeine Phosphate Tablets 6505-00-149-0116 6505-01-086-1992 6505-01-091-7535

6505-01-091-7535 Demil Restrictions 6505-01-091-7535

DEMIL: A | DEMILI: 1 | CRITICALITY: X | HMIC: P | PMIC: U | EDC: | ADPEC:

6505-01-091-7535 is a Usp Aspirin And Codeine Phosphate Tablets that does not have a nuclear hardened feature or any other critical feature such as tolerance, fit restriction or application. Demilitarization of this item has been confirmed and is not currently subject to changes. This item is considered a low risk when released from the control of the Department of Defense. The item may still be subject to the requirements of the Export Administration Regulations (EAR) and the Code of Federal Regulations (CFR). This item may be hazardous as it is in a Federal Supply Class for potentially hazardous items. A MSDS should be available from the supplier for the end user to evaluate any hazards. The precious metals content of this item is unknown.

6505-01-091-7535 End Users End Users 6505-01-091-7535

NASA (G65V)
Effective Date:
1 Apr 1991

6505-01-091-7535 Manufacturers Approved Sources 6505-01-091-7535

6505-01-091-7535 Technical Data Datasheet 6505-01-091-7535

Characteristic
Specifications
Active Medicament Medicinal Strength [AKJA]
60.000 Milligrams Codeine Phosphate Active Ingredient And 325.000 Milligrams Aspirin Active Ingredient
Administration [CSGS]
Oral
Primary Container Type [CQCT]
Strip, Roll
Primary Container Content Quantity [CRLK]
25.000 Tablets
Special Features [FEAT]
Reverse Numbered Strip
Total Primary Container Quantity [CSCW]
1

6505-01-091-7535 Related Items NATO Stock Numbers Related to 6505-01-091-7535

6505-01-091-7535 Freight Data Freight Information 6505-01-091-7535

6505-01-091-7535 has freight characteristics.. 6505-01-091-7535 has a variance between NMFC and UFC when transported by rail and the description should be consulted.